No connection

Search Results

ENOV vs WVE

ENOV
Enovis Corporation
NEUTRAL
Price
$24.10
Market Cap
$1.39B
Sector
Healthcare
AI Confidence
80%
WVE
Wave Life Sciences Ltd.
BEARISH
Price
$7.31
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ENOV
--
WVE
--
Forward P/E
ENOV
6.03
WVE
-5.46
P/B Ratio
ENOV
0.93
WVE
2.65
P/S Ratio
ENOV
0.62
WVE
32.21
EV/EBITDA
ENOV
7.38
WVE
-3.77

Profitability

Gross Margin
ENOV
60.88%
WVE
0.0%
Operating Margin
ENOV
6.09%
WVE
-327.44%
Profit Margin
ENOV
-52.69%
WVE
0.0%
ROE
ENOV
-58.27%
WVE
-54.97%
ROA
ENOV
1.09%
WVE
-27.18%

Growth

Revenue Growth
ENOV
2.6%
WVE
-79.4%
Earnings Growth
ENOV
--
WVE
--

Financial Health

Debt/Equity
ENOV
0.92
WVE
0.03
Current Ratio
ENOV
2.02
WVE
6.47
Quick Ratio
ENOV
0.8
WVE
6.35

Dividends

Dividend Yield
ENOV
--
WVE
--
Payout Ratio
ENOV
0.0%
WVE
0.0%

AI Verdict

ENOV NEUTRAL

Enovis Corporation presents a classic 'deep value' paradox, characterized by a stable Piotroski F-Score of 4/9 but severe bottom-line profitability issues. While the company trades at a significant discount to book value (P/B 0.93) and a very low forward P/E (6.03), its net profit margin is deeply negative at -52.69%. The stock is supported by a strong track record of earnings beats and bullish analyst targets, but this is countered by a disastrous long-term price trend and high execution risk associated with its acquisition-led growth strategy.

Strengths
Extreme valuation discount with Price/Book at 0.93 and Price/Sales at 0.62
Strong gross margins of 60.88% indicating a healthy core product value
Exceptional earnings track record with consistent beats over 25 quarters
Risks
Severe net losses resulting in a profit margin of -52.69% and negative ROE
High integration risk due to an aggressive acquisition-led growth strategy
Strong bearish technical momentum with a 5-year price decline of 68.9%
WVE BEARISH

WVE exhibits severe financial distress from a deterministic standpoint, highlighted by a critical Piotroski F-Score of 1/9. While the company maintains a strong liquidity position with a current ratio of 6.47 and negligible debt, these are offset by a catastrophic 79.4% decline in year-over-year revenue and an operating margin of -327.44%. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling by the CEO and CFO, alongside a recent 37% price collapse. The valuation is purely speculative, as evidenced by a Price/Sales ratio of 32.21 in the face of shrinking revenues.

Strengths
Very low Debt/Equity ratio (0.03)
Strong short-term liquidity (Current Ratio 6.47)
High analyst target price ($24.93) suggesting potential clinical catalysts
Risks
Severe revenue contraction (-79.4% YoY)
Extreme operational inefficiency (Operating Margin -327.44%)
Consistent failure to meet earnings estimates (0/4 beats in last 4 quarters)

Compare Another Pair

ENOV vs WVE: Head-to-Head Comparison

This page compares Enovis Corporation (ENOV) and Wave Life Sciences Ltd. (WVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile